Japan Earnings Highlights: Takeda, Astellas And Eisai
This article was originally published in PharmAsia News
Executive Summary
Takeda preps for cost-cutting program; Astellas clears path for Xtandi; and Eisai leans on Belviq in the U.S. with aggressive coverage program.